OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments



EN
06/12/2024

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D....

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment...

August 25, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D....

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye dr...

August 25, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Oculis Reports Q2 2025 Financial Results and Provides Company Update ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology. OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026 for the first potential eye drop to treat diabetic macular edema (DME) Privosegtor (OCS-05): Preparing to initiate Phase 2/3 trial in acute optic neuritis (AON) in 1H 2026 following positive Ph2 ACUITY results, and expanding clinical development into two new indications a...

August 21, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í ...

Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri félagsins ZUG, Sviss, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Á öðrum ársfjórðungi 2025 vann Oculis markvisst að áframhaldandi þróun lyfja á sviði augn- og augntaugasjúkdóma. OCS-01: Innritun sjúklinga í báðar DIAMOND fasa 3 lykilrannsóknirnar er lokið og búist er við fyrstu niðurstöðum (e. topline results) á öðrum ársfjórðungi 2026 fyrir fyrstu hugsanlegu augndropameðferðina við sjónhimnubjúg af völdum sykursýki (DME) Privosegtor (OCS-05): Nú stendur yfir undirbúningur fyrir fasa 2/3 rannsókn á bráðri sjóntaugabólg...

August 21, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Oculis Reports Q2 2025 Financial Results and Provides Company Update Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmologyOCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026 for the first potential eye drop to treat diabetic macular edema (DME)Privosegtor (OCS-05): Preparing to initiate Phase 2/3 trial in acute optic neuritis (AON) in 1H 2026 following positive Ph2 ACUITY results, and expanding clinical development into two new indications as the first potential neuroprotective treatment for non-art...

August 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch